S described by TRPV Activator Formulation Faderl et al. (9). o Considering all episodes of neutropenia. p HEPA, high-efficiency particulate air; MDS, myelodysplastic syndrome.16 (76) five (24) 14 (67) ten (48)77 (74) 27 (26) 37 (36) 19 (18)0.82 0.99 0.ten 0.006 0.and anti-Aspergillus triazole prophylaxis individuals (13 and ten P 0.73).DISCUSSION4 (19)71 (68) 0.12 (57) 1 (1) 23 (161)54 (52) 3 (1) 47 (280)0.In a prior epidemiological analysis of IFIs within the AML population, we discovered substantially greater IFI prices in the course of remissioninduction chemotherapy (RIC) among individuals who received prophylaxis with an echinocandin than among people that received mold-active triazoles (voriconazole or posaconazole) (7.1 versus 1.1 per 1,000 prophylaxis days, P 0.0001) (three). Offered the somewhat restricted proof supporting front-line use of echinocandins for key prophylaxis in AML, we suspected that echinocandin prophylaxis might have already been applied predominantly in older or higher-risk AML individuals (i.e., those with chemotherapy-associated AML) who had many comorbidities that prevented use of a triazole. Alternatively, echinocandin prophylaxis may happen to be applied much more often for individuals whose drug interactions or danger for enhanced hepatic toxicity with investigational chemotherapy was a concern (three), which precluded the usage of voriconazole orMay 2014 Volume 58 Numberaac.asm.orgGomes et al.TABLE two Clinical and treatment-associated threat things for IFI and mortality among AML sufferers who received voriconazole/posaconazole versus echinocandin primary antifungal prophylaxisDemographic or clinical characteristicp Male, n ( ) Median age (IQR), yrs Race, white, n ( ) Admission to the HEPA filter room in the course of FRIC, n ( ) Underlying circumstances,a n ( ) Lung illness or infectionb Bacterial infectionc Cardiovascular disease or condition Diabetes mellitus or induced hyperglycemiad Renal failuree Abnormal liver testf Other malignancyg Chemotherapy na e WHO AML classifications,h n ( ) Therapy-related AML MDS-related modifications Recurrent genetic abnormalities Myeloid sarcoma Acute leukemia of ambiguous lineage Not otherwise specified Cytogenetic danger group,i n ( ) Favorable Intermediate I Intermediate II Adverse FRIC protocol, n ( ) Cytarabine-containing regimen Other regimen Investigational chemotherapyj Clofarabine-containing protocolk General remission,l n ( ) Neutropenia (ANC 500 cells/mm3) At start of PAP drug, n ( ) Median no. of episodes (IQR) Median duration (IQR),m days Main antifungal prophylaxis Median no. of days to begin PAP after FRIC, (IQR) Median duration of prophylaxis (IQR),n days Prophylaxis periods 5 days,n n ( ) Concomitant fluconazole use, n ( ) Voriconazole/ posaconazole Echinocandin (n 42) (n 38) P 26 (62) 66 (381) 33 (79) 10 (24) 23 (61) 69 (617) 30 (79) 16 (42) 0.9 0.03 0.97 0.TABLE 2 (Continued)Demographic or clinical characteristicp Voriconazole/ posaconazole Echinocandin (n 42) (n 38) P 21 (39) 0.Median duration of fluconazole use 11 (51) (days),o IQRa b11 (26) 9 (21) 15 (36) six (14) 7 (17) five (12) six (14) 38 (90)7 (18) three (8) 11 (29) 7 (18) 7 (18) four (11) eight (21) 35 (92)0.41 0.12 0.52 0.62 0.84 0.99 0.43 0.1/41 (two) 15/41 (37) 12/41 (29) 1/41 (2) 0/41 (0) 13/41 (32)3/38 (five) 13/38 (34) 8/38 (21) 1/38 (three) 1/38 (three) 14/38 (37)0.61 0.83 0.four 0.99 0.48 0.At-NK1 Modulator review hospital admission or history. Lung infection at hospital admission or concomitant to AML history. c At-hospital admission or concomitant to AML history according to patient’s treating doctor according to clinical, microbiology.
